Cargando…

How to manage patients with suspected upper tract urothelial carcinoma in the pandemic of COVID-19?

BACKGROUND: The pandemic of COVID-19 has disrupted the clinical pathway for patients with suspected upper tract urothelial carcinoma (UTUC). This aims to investigate the optimal management of UTUC during the pandemic by determining 1) Whether a three-month delay of RNU leads to worsened overall surv...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Hsiang-Ying, Chan, Erica On-Ting, Li, Ching-Chia, Leung, David, Li, Wei-Ming, Yeh, Hsin-Chih, Chiu, Peter Ka-Fung, Ke, Hung-Lung, Yee, Chi-Hang, Wong, Joseph Hon-Ming, Ng, Chi-Fai, Teoh, Jeremy Yuen-Chun, Wu, Wen-Jeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Published by Elsevier Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8318925/
https://www.ncbi.nlm.nih.gov/pubmed/34332847
http://dx.doi.org/10.1016/j.urolonc.2021.06.007
_version_ 1783730348645941248
author Lee, Hsiang-Ying
Chan, Erica On-Ting
Li, Ching-Chia
Leung, David
Li, Wei-Ming
Yeh, Hsin-Chih
Chiu, Peter Ka-Fung
Ke, Hung-Lung
Yee, Chi-Hang
Wong, Joseph Hon-Ming
Ng, Chi-Fai
Teoh, Jeremy Yuen-Chun
Wu, Wen-Jeng
author_facet Lee, Hsiang-Ying
Chan, Erica On-Ting
Li, Ching-Chia
Leung, David
Li, Wei-Ming
Yeh, Hsin-Chih
Chiu, Peter Ka-Fung
Ke, Hung-Lung
Yee, Chi-Hang
Wong, Joseph Hon-Ming
Ng, Chi-Fai
Teoh, Jeremy Yuen-Chun
Wu, Wen-Jeng
author_sort Lee, Hsiang-Ying
collection PubMed
description BACKGROUND: The pandemic of COVID-19 has disrupted the clinical pathway for patients with suspected upper tract urothelial carcinoma (UTUC). This aims to investigate the optimal management of UTUC during the pandemic by determining 1) Whether a three-month delay of RNU leads to worsened overall survival, 2) Whether radical nephroureterectomy (RNU) can be performed without prior diagnostic ureteroscopy (URS). METHODS: Consecutive patients with RNU performed for suspected UTUC in four hospitals in Hong Kong and Taiwan were included. Patients with histologically proven UTUC and with RNU performed within one year were dichotomized into early (≤3 months) and delayed (>3 months) RNU groups. Diagnostic performances of predictive models based on pre-URS factors (gross haematuria, suspicious or malignant urine cytology, and filling defect or contrast-enhancing mass on computed tomography), with or without URS, were analysed using receiver operating characteristics and area under curve (AUC). Overall survival was analysed using Kaplan-Meier method and multivariate Cox regression analysis. RESULTS: Between 2000 and 2019, 665 patients underwent RNU, and 491 of them had prior diagnostic URS. The early RNU group had a better overall survival (P = 0.015). Early RNU was associated with a better overall survival upon multivariate analysis (HR 1.55, 95% CI 1.03–2.33, P = 0.035). Large tumour size, multi-focal tumour, T2 or above disease, and positive nodal status were associated with a poorer overall survival. A combination of any 2 out of the 3 pre-URS factors achieved a positive predictive value of 99.5 to 100%. Presence of all 3 pre-URS factors achieved an AUC of 0.851 with URS, and AUC of 0.809 without URS. CONCLUSIONS: A delay of RNU for over 3 months was associated with poorer overall survival and has to be avoided despite the current COVID-19. We can also consider direct RNU based on clinical factors alone. This also avoids URS hospitalization and expedites the clinical pathway of UTUC.
format Online
Article
Text
id pubmed-8318925
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Published by Elsevier Inc.
record_format MEDLINE/PubMed
spelling pubmed-83189252021-07-29 How to manage patients with suspected upper tract urothelial carcinoma in the pandemic of COVID-19? Lee, Hsiang-Ying Chan, Erica On-Ting Li, Ching-Chia Leung, David Li, Wei-Ming Yeh, Hsin-Chih Chiu, Peter Ka-Fung Ke, Hung-Lung Yee, Chi-Hang Wong, Joseph Hon-Ming Ng, Chi-Fai Teoh, Jeremy Yuen-Chun Wu, Wen-Jeng Urol Oncol Clinical-Bladder cancer BACKGROUND: The pandemic of COVID-19 has disrupted the clinical pathway for patients with suspected upper tract urothelial carcinoma (UTUC). This aims to investigate the optimal management of UTUC during the pandemic by determining 1) Whether a three-month delay of RNU leads to worsened overall survival, 2) Whether radical nephroureterectomy (RNU) can be performed without prior diagnostic ureteroscopy (URS). METHODS: Consecutive patients with RNU performed for suspected UTUC in four hospitals in Hong Kong and Taiwan were included. Patients with histologically proven UTUC and with RNU performed within one year were dichotomized into early (≤3 months) and delayed (>3 months) RNU groups. Diagnostic performances of predictive models based on pre-URS factors (gross haematuria, suspicious or malignant urine cytology, and filling defect or contrast-enhancing mass on computed tomography), with or without URS, were analysed using receiver operating characteristics and area under curve (AUC). Overall survival was analysed using Kaplan-Meier method and multivariate Cox regression analysis. RESULTS: Between 2000 and 2019, 665 patients underwent RNU, and 491 of them had prior diagnostic URS. The early RNU group had a better overall survival (P = 0.015). Early RNU was associated with a better overall survival upon multivariate analysis (HR 1.55, 95% CI 1.03–2.33, P = 0.035). Large tumour size, multi-focal tumour, T2 or above disease, and positive nodal status were associated with a poorer overall survival. A combination of any 2 out of the 3 pre-URS factors achieved a positive predictive value of 99.5 to 100%. Presence of all 3 pre-URS factors achieved an AUC of 0.851 with URS, and AUC of 0.809 without URS. CONCLUSIONS: A delay of RNU for over 3 months was associated with poorer overall survival and has to be avoided despite the current COVID-19. We can also consider direct RNU based on clinical factors alone. This also avoids URS hospitalization and expedites the clinical pathway of UTUC. Published by Elsevier Inc. 2021-10 2021-06-17 /pmc/articles/PMC8318925/ /pubmed/34332847 http://dx.doi.org/10.1016/j.urolonc.2021.06.007 Text en © 2021 Published by Elsevier Inc. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Clinical-Bladder cancer
Lee, Hsiang-Ying
Chan, Erica On-Ting
Li, Ching-Chia
Leung, David
Li, Wei-Ming
Yeh, Hsin-Chih
Chiu, Peter Ka-Fung
Ke, Hung-Lung
Yee, Chi-Hang
Wong, Joseph Hon-Ming
Ng, Chi-Fai
Teoh, Jeremy Yuen-Chun
Wu, Wen-Jeng
How to manage patients with suspected upper tract urothelial carcinoma in the pandemic of COVID-19?
title How to manage patients with suspected upper tract urothelial carcinoma in the pandemic of COVID-19?
title_full How to manage patients with suspected upper tract urothelial carcinoma in the pandemic of COVID-19?
title_fullStr How to manage patients with suspected upper tract urothelial carcinoma in the pandemic of COVID-19?
title_full_unstemmed How to manage patients with suspected upper tract urothelial carcinoma in the pandemic of COVID-19?
title_short How to manage patients with suspected upper tract urothelial carcinoma in the pandemic of COVID-19?
title_sort how to manage patients with suspected upper tract urothelial carcinoma in the pandemic of covid-19?
topic Clinical-Bladder cancer
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8318925/
https://www.ncbi.nlm.nih.gov/pubmed/34332847
http://dx.doi.org/10.1016/j.urolonc.2021.06.007
work_keys_str_mv AT leehsiangying howtomanagepatientswithsuspecteduppertracturothelialcarcinomainthepandemicofcovid19
AT chanericaonting howtomanagepatientswithsuspecteduppertracturothelialcarcinomainthepandemicofcovid19
AT lichingchia howtomanagepatientswithsuspecteduppertracturothelialcarcinomainthepandemicofcovid19
AT leungdavid howtomanagepatientswithsuspecteduppertracturothelialcarcinomainthepandemicofcovid19
AT liweiming howtomanagepatientswithsuspecteduppertracturothelialcarcinomainthepandemicofcovid19
AT yehhsinchih howtomanagepatientswithsuspecteduppertracturothelialcarcinomainthepandemicofcovid19
AT chiupeterkafung howtomanagepatientswithsuspecteduppertracturothelialcarcinomainthepandemicofcovid19
AT kehunglung howtomanagepatientswithsuspecteduppertracturothelialcarcinomainthepandemicofcovid19
AT yeechihang howtomanagepatientswithsuspecteduppertracturothelialcarcinomainthepandemicofcovid19
AT wongjosephhonming howtomanagepatientswithsuspecteduppertracturothelialcarcinomainthepandemicofcovid19
AT ngchifai howtomanagepatientswithsuspecteduppertracturothelialcarcinomainthepandemicofcovid19
AT teohjeremyyuenchun howtomanagepatientswithsuspecteduppertracturothelialcarcinomainthepandemicofcovid19
AT wuwenjeng howtomanagepatientswithsuspecteduppertracturothelialcarcinomainthepandemicofcovid19